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Background: HeartMate II (HM II) and HeartWare (HW) Left Ventricular Assist Devices have been successfully used
in end-stage heart failure patients as a bridge to transplantation, recovery, or decision. We set out to compare their
effect in off-loading the left ventricle and its geometry.
Methods: The left ventricular end diastolic (LVEDD) and end systolic (LVESD) diameters were compared between
first time HM II (n = 25) and HW implantations (n = 24) before and after the operation at 1, 3, and 6 months. A p
value of less than 0.05 was considered as significant.
Results: Post-operative LVEDD and LVESD at 1, 3, and 6 months were significantly reduced in comparison with pre-
operative values in both HM II and HW groups. No significant difference was found comparing HM II and HW
groups together before and after the operation.
Conclusions: Our study shows that both HM II and HW can significantly reduce the left ventricular systolic and
diastolic dimensions and off-load the left ventricle. The miniaturized nature of HW does not affect its performance
and it could be as effective as HM II.
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Mechanical circulatory support for patients with
advanced heart failure has evolved considerably during
the past 30 years and is now the standard therapy at
many medical centers worldwide [1]. Ventricular Assist
Devices (VAD) have been mainly used as a bridge to
transplantation. Nowadays, as a result of donor shortage
and the success of the newer devices, they are also
considered as a bridge to recovery or a bridge to deci-
sion [2].
In the last decade, the smaller second generation
continuous-flow assist devices have successfully replaced
their first generation pulsatile predecessors. They have
proved to be more reliable, smaller in size, and have* Correspondence: morteza.tavakkoli@gmail.com;
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reproduction in any medium, provided the orlower rates of adverse events (infection, bleeding, stroke,
and device failure). The most common second gener-
ation devices currently used are HeartMate II (Thortec
Inc.) [3], Micromed Debakey [4], Berlin Heart Incor
(Berlin Heart AG) [5], and Jarvik 2000 (Jarvik Heart
Inc.) [6]. HeartMate II is the most successful and widely
used second generation VAD.
Another recent addition to this family is HeartWare
VAD (HeartWare Inc). It is a miniaturized centrifugal
blood pump that could be placed intra-pericardially,
thereby avoiding abdominal surgery and pump pocket
formation. It has proved to provide satisfactory long
term survival with excellent quality of life, low rate of
adverse events and feasibility for implantation via min-
imally invasive incisions [7-10]. There has been a debate
if the miniaturized nature of the pump could affect its
effect on off-loading of the left ventricle, in comparison
with the bigger second generation VAD systems. We set
out to compare the effect of HeartWare (HW) andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Pre-operative patients’ demographics
Number Male Female Age
HeartMate II 25 19 (76%) 6 (24%) 41.32 +/− 12.29
HeartWare 24 19 (79%) 5 (21%) 50.29 +/− 11.91
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Methods
First time HM II and HW implantations for Dilated
Cardio-Myopathy performed at Harefield Hospital from
April 2008 to October 2010 were included in this study.
Pre-operative and post-operative (first month and then
three-monthly) echocardiography is performed at
Harefield Hospital as a routine follow up procedure for
all patients with a VAD implantation. Echocardiography
data is inclusive of the left ventricular systolic diameter
and the left ventricular diastolic diameter at baseline
VAD pump speed (9600 rpm for HM II and 2800 rpm
for HW).
This data was part of Harefield Hospital post VAD
surgery data collection and outcome evaluation. The
study was categorized as a Service Evaluation by the Eth-
ical Committee and required no need for ethical
approval.
Fisher’s exact test was used for comparing the demo-
graphic factors, and the mortality. Pre-operative left
ventricular parameters were compared with the post-
operative left ventricular parameters at 1, 3, and 6 -
months after the operation, using Analysis of Variance
(ANOVA) test. A p value of less than 0.05 was
considered as significant. The study design was a retro-
spective review of the prospectively collected data.
Results
HM II and HW groups contained 25 and 24 patients re-
spectively. All patients had a history of Dilated Cardio-
Myopathy with NYHA class 4 symptoms. Table 1 showsTable 2 Pre and post VAD implantation left ventricular diame
Pre operative 1 Mont
HM II LVEDD mm 72.8 +/− 9.3 54.7 +/−
HW LVEDD mm 68.9 +/− 10.1 57.5 +/−
HM II LVEDD% *** −25.1 +
HW LVEDD% *** −17.3 +
HM II LVESD mm 66.0 +/− 9.3 47.0 +/−
HW LVESD mm 59.8 +/− 10.7 51.1 +/−
HM II LVESD% *** −28.4 +
HW LVESD% *** −17.0 +
HM II: HeartMate II; HW: HeartWare; LVEDD: Left Ventricular End Diastolic Diameter
Diastolic Diameter change compared to each patient’s pre-operative value; LVESD%
pre-operative value.the demographics of the two groups. The mean age in
HW group (50.29) was significantly higher than the
mean age in HM II group (41.32). Six months mortality
in HM II and HW groups were 9 (36%) and 4 (16%) re-
spectively, with no significant difference. Table 2 shows
the systolic and diastolic left ventricular diameters before
and after VAD implantation. There was a significant dif-
ference between pre-operative and post-operative left
ventricular diameters in each group. No significant dif-
ference was noticed in post-operative left ventricular
diameters of each group. When comparing HM II and
HW groups together, there was no significant difference
in the pre-operative or post-operative left ventricular
diameters in between the two groups.
Discussion
Ventricular Assist Device systems have revolutionized
the management of end stage heart failure. They are
used as a bridge to transplantation, recovery, or decision
[1,2,7-9,11]. There is a growing trend towards the use of
smaller and more compact devices, with the aim of
avoiding abdominal surgery, pump pocket formation,
and reduction of the adverse events. Smaller devices also
provide the chance for minimally invasive incisions, in-
stead of a conventional median sternotomy [10]. HM II
is the most successful and widely used second gener-
ation VAD system [1-3]. Echocardiographic studies show
that HM II reduces the left ventricular end-diastolic di-
mension by 21% and 35%, one week and 4 months after
VAD implantation respectively [12]. It has been quoted
that patients with a relatively small left ventricular end
diastolic diameters (<63 mm) have a significantly higher
risk for in-hospital mortality [13]. Maybaum et al.
reported in their study for cardiac recovery that
HeartMate, Novacor, and Debakey VAD systems signifi-
cantly decrease the left ventricular end diastolic
diameters at 1, 2, 3, and 4 months after VAD implant-
ation [14]. In the initial clinical experience with HW, no
comparison was made between the pre-operative andters
h 3 Months 6 Months
16.7 54.1 +/− 14.5 56.5 +/− 13.7
10.4 57.9 +/− 11.2 59.3 +/− 8.2
/− 21.0 −27.3 +/− 17.1 −24.7 +/− 15.4
/− 13.0 −17.7 +/− 16.5 −14.9 +/− 12.3
15.8 44.5 +/− 16.2 45.9 +/− 15.3
12.5 50.1 +/− 11.7 50.6 +/− 8.5
/− 21.9 −34.2 +/− 20.0 −32.9 +/− 18.9
/− 17.1 −19.5 +/− 19.7 −18.3 +/− 15.2
; LVESD: Left Ventricular End Systolic Diameter; LVEDD%: Left Ventricular End
: Left Ventricular End Systolic Diameter change compared to each patient’s
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study confirms that HW significantly reduces the left
ventricular systolic and diastolic dimensions and off-load
the left ventricle in the short and long term. The
miniaturized nature of the pump does not affect its per-
formance, as no significant difference was noticed while
comparing HW and HM II. We did not checked for the
left ventricular dimensions at partial pump support/
pump off status, as the aim of the study was not to
check for myocardial recovery. Myocardial recovery is a
debatable discussion in the current era with so many
proponents and opponents [11,14]. Groups were not
sub-analyzed based on the etiology of Dilated Cardio-
Myopathy. Ethiology affects the outcome and the potential
for recovery, but not the mechanical ability of the device in
off-loading the left ventricle. So far, the implantation of
smaller VAD systems via median sternotomy or minimally
invasive incisions, has proved to be successful with
satsifactory clinical and echocardiographic results [7,8,10].
Conclusions
Our study shows that both HM II and HW can signifi-
cantly reduce the left ventricular systolic and diastolic
dimensions and off-load the left ventricle. The
miniaturized nature of HW does not affect its perform-
ance and it could be as effective as HM II.
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